Successful Pharmacokinetic (PK)-Directed Dosing of Evomela ® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

High-dose melphalan prior to AHCT for MM and AL patients is currently given as a fixed dose based on body surface area leading to inter-patient differences in area under the curve (AUC). Increased exposure (higher AUC) leads to increased toxicity, but longer survival (Shaw et al., BBMT 2012). To optimize therapy, we evaluated the feasibility of PK-directed dosing of PGF-MEL (Acrotech Biopharma), a more stable and possibly less toxic intravenous formulation of melphalan.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Gunjan Shah, Andrew Lin, Angela Grumley, Alyssa Kamrowski, Ryan Schofield, Sean Devlin, Valkal Bhatt, Anthony Proli, David Chung, Parastoo Dahi, Oscar Lahoud, Michael Scordo, Dean Carlow, Sergio Giralt, Heather Landau Source Type: research